Notably, although many studies have indicated the clinical relevance of PD-L1 positive CTCs in various cancers, including NSCLC [14, 20–23], there is still controversy, and the analysis of CTCs is dependent on the use of different clones of anti-PD-L1 antibodies and CTCs enrichment techniques. Here, CD274 is linked to cancer.